These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 29129444)

  • 21. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma.
    Xu HX; Liu L; Xiang JF; Wang WQ; Qi ZH; Wu CT; Liu C; Long J; Xu J; Ni QX; Yu XJ
    Surgery; 2017 Feb; 161(2):373-384. PubMed ID: 27838102
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chronologic changes in clinical and survival features of pancreatic ductal adenocarcinoma since 2000: A single-center experience with 2,029 patients.
    Shin SH; Kim SC; Song KB; Hwang DW; Lee JH; Park KM; Lee YJ
    Surgery; 2018 Sep; 164(3):432-442. PubMed ID: 29884479
    [TBL] [Abstract][Full Text] [Related]  

  • 23. What is the major prognostic factor in tumor-node-metastasis staging of pancreatic adenocarcinoma?
    Santi I; Brandt A; Hemminki K
    Ann Surg Oncol; 2011 Jan; 18(1):300-1. PubMed ID: 20589435
    [No Abstract]   [Full Text] [Related]  

  • 24. Label-free proteomics reveals serum proteins whose levels differ between pancreatic ductal adenocarcinoma patients with short or long survival.
    Holm M; Saraswat M; Joenväärä S; Seppänen H; Renkonen R; Haglund C
    Tumour Biol; 2020 Jun; 42(6):1010428320936410. PubMed ID: 32586207
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adverse oncologic effects of intraoperative transfusion during pancreatectomy for left-sided pancreatic cancer: the need for strict transfusion policy.
    Hwang HK; Jung MJ; Lee SH; Kang CM; Lee WJ
    J Hepatobiliary Pancreat Sci; 2016 Aug; 23(8):497-507. PubMed ID: 27295957
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pancreatic volume is one of the independent prognostic factors for resectable pancreatic ductal adenocarcinomas.
    Fukumoto T; Watanabe T; Hirai I; Kimura W
    J Hepatobiliary Pancreat Sci; 2016 Aug; 23(8):472-9. PubMed ID: 27246905
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The treatment of pancreatic cancer.
    Yeo CJ; Cameron JL
    Ann Chir Gynaecol; 2000; 89(3):225-33. PubMed ID: 11079793
    [No Abstract]   [Full Text] [Related]  

  • 28. Follow-up after curative surgery for pancreatic ductal adenocarcinoma: asymptomatic recurrence is associated with improved survival.
    Nordby T; Hugenschmidt H; Fagerland MW; Ikdahl T; Buanes T; Labori KJ
    Eur J Surg Oncol; 2013 Jun; 39(6):559-66. PubMed ID: 23498362
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Accuracy of Clinical Staging in Early-Stage Pancreatic Ductal Adenocarcinoma.
    Perrotta G; Mohamed G; Larson BK; Osipov A; Ferrone CR; Lo SK; Gaddam S
    JAMA; 2024 Oct; 332(13):1108-1110. PubMed ID: 39235802
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic significance of hepatocyte growth factor activator inhibitor type 1 (HAI-1) immunoreactivity in pancreatic ductal adenocarcinoma.
    Sakugawa C; Haruyama Y; Tanaka H; Fukushima T; Kawaguchi M; Kataoka H
    BMC Res Notes; 2017 Dec; 10(1):674. PubMed ID: 29202869
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumoral EHF predicts the efficacy of anti-PD1 therapy in pancreatic ductal adenocarcinoma.
    Liu J; Jiang W; Zhao K; Wang H; Zhou T; Bai W; Wang X; Zhao T; Huang C; Gao S; Qin T; Yu W; Yang B; Li X; Fu D; Tan W; Yang S; Ren H; Hao J
    J Exp Med; 2019 Mar; 216(3):656-673. PubMed ID: 30733283
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumour epithelial vimentin expression and outcome of pancreatic ductal adenocarcinomas.
    Handra-Luca A; Hong SM; Walter K; Wolfgang C; Hruban R; Goggins M
    Br J Cancer; 2011 Apr; 104(8):1296-302. PubMed ID: 21448168
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A clinically feasible multiplex proteomic immunoassay as a novel functional diagnostic for pancreatic ductal adenocarcinoma.
    Lim KH; Langley E; Gao F; Luo J; Li L; Meyer G; Kim P; Singh S; Kushnir VM; Early DS; Mullady DK; Edmundowicz SA; Wani S; Murad FM; Cao D; Azar RR; Wang-Gillam A
    Oncotarget; 2017 Apr; 8(15):24250-24261. PubMed ID: 28445954
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PROX1 and β-catenin are prognostic markers in pancreatic ductal adenocarcinoma.
    Saukkonen K; Hagström J; Mustonen H; Juuti A; Nordling S; Kallio P; Alitalo K; Seppänen H; Haglund C
    BMC Cancer; 2016 Jul; 16():472. PubMed ID: 27411302
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Can Neoadjuvant Therapy in Pancreatic Cancer Increase the Pool of Patients Eligible for Pancreaticoduodenectomy?
    Hackert T; Ulrich A; Büchler MW
    Adv Surg; 2017 Sep; 51(1):1-10. PubMed ID: 28797331
    [No Abstract]   [Full Text] [Related]  

  • 36. Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment.
    Philip PA; Mooney M; Jaffe D; Eckhardt G; Moore M; Meropol N; Emens L; O'Reilly E; Korc M; Ellis L; Benedetti J; Rothenberg M; Willett C; Tempero M; Lowy A; Abbruzzese J; Simeone D; Hingorani S; Berlin J; Tepper J
    J Clin Oncol; 2009 Nov; 27(33):5660-9. PubMed ID: 19858397
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical importance of intraoperative peritoneal cytology in patients with pancreatic cancer.
    Abe T; Ohuchida K; Endo S; Ookubo F; Mori Y; Nakata K; Miyasaka Y; Manabe T; Ohtsuka T; Nagai E; Oda Y; Nakamura M
    Surgery; 2017 Apr; 161(4):951-958. PubMed ID: 27939334
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression and prognosis value of SHP2 in patients with pancreatic ductal adenocarcinoma.
    Zheng J; Huang S; Huang Y; Song L; Yin Y; Kong W; Chen X; Ouyang X
    Tumour Biol; 2016 Jun; 37(6):7853-9. PubMed ID: 26695153
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preoperative chemoradiation reduces the risk of pancreatic fistula after distal pancreatectomy for pancreatic adenocarcinoma.
    Takahashi H; Ogawa H; Ohigashi H; Gotoh K; Yamada T; Ohue M; Miyashiro I; Noura S; Kishi K; Motoori M; Shingai T; Nakamura S; Nishiyama K; Yano M; Ishikawa O
    Surgery; 2011 Sep; 150(3):547-56. PubMed ID: 21621236
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma.
    Tessier-Cloutier B; Kalloger SE; Al-Kandari M; Milne K; Gao D; Nelson BH; Renouf DJ; Sheffield BS; Schaeffer DF
    BMC Cancer; 2017 Sep; 17(1):618. PubMed ID: 28870260
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.